A cancer drug, first tested in mice, has successfully stopped the growth of cancer in patients with untreatable conditions.
The drug (ATX-101) – developed by researchers at the Norwegian University of Science and Technology (NTNU), and its spin-off company APIM Therapeutics – only targets cancer cells and not other healthy cells in the body.
The drug can be given on its own, or be used in combination with chemotherapy to make it more effective. In addition, it does not cause hair loss, unlike common forms of chemotherapy.
ATX-101 is currently in a phase II trial and will then be tested on cancer patients with sarcoma, which affects the connective tissue.
End